London: Sage Therapeutics said on Tuesday its experimental drug was found to be safe and showed some effect in patients with a rare, genetic neurological condition called Huntington’s disease in a part of a mid-stage study.

The company, however, said the study in Huntington’s disease patients was not designed to show a statistically significant difference between the drug dalzanemdor and placebo.

Shares of the company, which soared 80 per cent initially, erased those gains and were down 1.6 per cent in volatile premarket trading.

The news follows a mid-stage trial failure for the same drug, in April when it was tested in patients with Parkinson’s disease.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)

  • Published On Jun 11, 2024 at 05:51 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App